GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (NAS:MIRA) » Definitions » Forward PE Ratio

Mira Pharmaceuticals (Mira Pharmaceuticals) Forward PE Ratio : 0.00 (As of Jun. 20, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mira Pharmaceuticals Forward PE Ratio?

Mira Pharmaceuticals's Forward PE Ratio for today is 0.00.

Mira Pharmaceuticals's PE Ratio without NRI for today is 0.00.

Mira Pharmaceuticals's PE Ratio for today is 0.00.


Mira Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Mira Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mira Pharmaceuticals Forward PE Ratio Chart

Mira Pharmaceuticals Annual Data
Trend
Forward PE Ratio

Mira Pharmaceuticals Quarterly Data
Forward PE Ratio

Competitive Comparison of Mira Pharmaceuticals's Forward PE Ratio

For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mira Pharmaceuticals's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Mira Pharmaceuticals's Forward PE Ratio falls into.



Mira Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Mira Pharmaceuticals  (NAS:MIRA) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Mira Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Mira Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mira Pharmaceuticals (Mira Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
855 N Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Its target patient population is also typically presenting with chronic pain. its drug candidate, MIRA1a, if approved by the FDA, maybe a significant advancement in the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by the company, it believes that MIRA1a enhances the therapeutic potential for treating anxiety, cognitive decline and chronic pain.
Executives
Brian Patrick Mcnulty 10 percent owner C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Brian Frederick Daly director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
George Cappy 10 percent owner C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
David C Vorhoff director C/O STAR SCIENTIFIC, INC., 801 LIBERTY WAY, CHESTER VA 23836
Chapman Christopher C Jr director, officer: Executive Chairman C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Adam Kaplin officer: Pres. & Chief Scientific Off. C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Michelle Yanez officer: CFO, Secretary & Treasurer 449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Hugh Iii Mccoll director 100 RIVER BLUFF DRIVE, SUITE 210, LITTLE ROCK AR 72202
Christos Nicholoudis director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bradley Kroenig director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Erez Aminov director, officer: Chief Executive Officer C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Talhia Tuck director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bay Shore Trust 10 percent owner C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173